Status:
TERMINATED
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
ICON plc
Covance
Conditions:
Hidradenitis Suppurativa
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to gain initial evidence for the safety, tolerability and efficacy of MEDI8968 for the treatment of subjects with moderate to severe hidradenitis suppurativa
Eligibility Criteria
Inclusion
- Hidradenitis suppurativa (HS) (moderate to severe)
- Diagnosis of HS for at least 1 year
- At least 5 active inflammatory lesions in at least 2 locations
- On a stable dose of antibiotics and/or analgesics for at least 4 weeks (if already taking these medications)
- Average pain score of 3-9.
Exclusion
- History of cyclic neutropenia
- Laboratory assessment abnormalities
- Underlying disorder considered unsuitable for inclusion
- Other skin diseases that may interfere with HS assessment
- Pregnancy or planning for pregnancy
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT01838499
Start Date
May 1 2013
End Date
October 1 2014
Last Update
September 1 2016
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Phoenix, Arizona, United States
2
Research Site
Bakersfield, California, United States
3
Research Site
Fremont, California, United States
4
Research Site
Los Angeles, California, United States